JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (3): 77-80.doi: 10.6040/j.issn.1671-7554.0.2015.929

Previous Articles     Next Articles

Relationship between mir-99a expression and prognosis of epithelial ovarian cancer

XU Zhihong1, WU Xiaohua2, YAO Tiezhu3, WANG Xiaoxiang1, DUAN Xiaoyang1, SHI Jian1   

  1. 1. Department of Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China;
    2. Department of Obstetrics and Gynaecology, Bethune International Peace Hospital, Shijiazhuang 050000, Hebei, China;
    3. Department of Cardiology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2015-09-28 Online:2016-03-10 Published:2016-03-10

PDF (PC)

396

Abstract: Objective To investigate the mir-99a expression in epithelial ovarian cancer(EOC), and its relationship with the clinicopathological features and prognosis. Methods The mir-99a expression in 137 cases of EOC tissues was detected with qRT-PCR assay. The correlation between mir-99a expression and clinicopathological features of EOC were analyzed. Survival curves for patients with different mir-99a expressions were plotted using the Kaplan-Meier method and compared using the log-rank test. Results The mir-99a expression reduced significantly in EOC tissues compared with that in adjacent normal tissues(P<0.001). Low mir-99a expression was significantly correlated with higher histological grade(P=0.027), lymph node metastasis(P=0.001), peritoneal metastasis(P<0.001), and higher FIGO stage(P<0.001). Kaplan-Meier analysis with log-rank test revealed that low mir-99a expression was correlated with short survival time of patients with EOC(log-rank test, P=0.005). Multivariate analysis showed that mir-99a expression was an independent prognostic factor for the overall survival(HR: 2.368, 95%CI: 1.621-10.925, P=0.016). Conclusion The mir-99a expression is an independent prognostic factor of patients with EOC. It can serve as a diagnostic and prognostic marker in clinical practice.

Key words: Epithelial ovarian cancer, Prognosis, mir-99a, Clinical pathology

CLC Number: 

  • R737.31
[1] Karimi-Zarchi M, Mortazavizadeh SM, Bashardust N, et al. The clinicopathologic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd, Iran[J]. Electron Physician, 2015, 7(6): 1399-1406. doi: 10.14661/1399. eCollection 2015.
[2] Cheng W, Liu J, Yoshida H, et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract[J]. Nature medicine, 2005, 11(5): 531-537.
[3] Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer[J]. Hormones Cancer, 2010, 1(6): 277-290.
[4] Jönsson JM, Skovbjerg Arildsen N, Malander S, et al. Sex steroid hormone receptor expression affects ovarian cancer survival[J]. Transl Oncol, 2015, 8(5): 424-433.
[5] Jiang H, Qu L, Wang Y, et al. miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells[J]. Biomedicine Pharmacotherapy, 2014, 68(2): 163-169.
[6] Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer[J]. J Pathol, 2011, 223(2): 102-115.
[7] Bushati N, Cohen SM. microRNA functions[J]. Annu Rev Cell Dev Biol, 2007, 23:175-205.
[8] Calin GA, Croce CM. MicroRNA signatures in human cancers[J]. Nature reviews Cancer, 2006, 6(11): 857-866.
[9] 何玲, 林功标, 程金妹. MicroRNA在头颈肿瘤的研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2010, 2: 170-173.
[10] Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis[J]. Cancer Res, 2007, 67(10): 4553-4555.
[11] Croce CM, Calin GA. miRNAs, cancer, and stem cell division[J]. Cell, 2005, 122(1): 6-7.
[12] Ahmed FE, Jeffries CD, Vos PW, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue[J]. Cancer Genomics Proteomics, 2009, 6(5): 281-295.
[13] Faruq O, Vecchione A. microRNA: Diagnostic Perspective[J]. Front Med, 2015, 2: 51. doi: 10.3389/fmed.2015.00051. eCollection 2015.
[14] Chen Z, Jin Y, Yu D, et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma[J]. Oral Oncol, 2012, 48(8): 686-691.
[15] Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma[J]. J Biol Chem, 2011, 286(42): 36677-36685.
[16] Sun D, Lee YS, Malhotra A, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation[J]. Cancer Res, 2011, 71(4): 1313-1324.
[17] Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer[J]. Cancer Res, 2009, 69(21): 8472-8481.
[18] Torres A, Torres K, Pesci A, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma[J]. BMC Cancer, 2012, 12: 369. doi: 10.1186/1471-2407-12-369
[19] Sun J, Chen Z, Tan X, et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma[J]. Med Oncol, 2013, 30(1): 411. doi: 10.1007/s12032-012-0411-9. Epub 2013 Jan 5.
[20] Cui L, Zhou H, Zhao H, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma[J]. BMC Cancer, 2012, 12: 546. doi: 10.1186/1471-2407-12-546.
[1] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[2] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[3] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[4] JIA Ruoxi, LYU Li, LIU Hanyun, WU Yinping, LI Fengcai, ZHAO Zehua, WANG Kai, FAN Yuchen. Diagnostic value of blood cell count-related biomarkers in predicting 28-day mortality in acute-on-chronic hepatitis b liver failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 89-99.
[5] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[6] YANG Weifang, XU Hong, LIU Yuantao, ZHAO Huichen. Mechanism of thyroid-stimulating immunoglobulin in Graves disease recurrence and clinical significance [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 116-121.
[7] LIU Wenzhao, ZHANG Yuan, MA Xiangping, WEI Fengtao, BU Peili. Correlation between the pre-endothelial activation and stress index and the mortality risk of patients with heart failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 27-35.
[8] CHEN Wenliang, WANG Huanhuan, HAO Jinjin, GONG Rui, ZHAO Qiang, ZHANG Fei, GAO Lei, DONG Jingxun. The role of lncRNA PVT1 in prognostic assessment and malignant progression of gastric cancer: a study based on nomogram model and functional cellular experiments [J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 61-71.
[9] GUO Shuhua, FAN Yang, TIAN Feng, WANG Chuanxin, DU Lutao, LI Peilong, GUO Xing, XU Shuo. Role of microfibril-associated protein 3 in regulating mesenchymal transition of glioma stem cells [J]. Journal of Shandong University (Health Sciences), 2024, 62(6): 9-16.
[10] WEI Yanruoxue, LI Ziqi, LIU Chuncheng, LIU Xiaohan, ZHAO Ran, LIU Yukun. Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 89-94.
[11] LIU Chuncheng, LIU Xiaohan, WEI Yanruoxue, LI Ziqi, LIU Yukun, ZHAO Ran. Subcellular localization pattern of bromodomain containing 9 in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 24-30.
[12] YANG Xueyan, WU Yinping, LYU Li, ZHAO Zehua, MA Hangyu, LI Fengcai, WANG Kai, FAN Yuchen. Diagnostic value of dynamic changes of monocyte-to-lymphocyte ratio in acute-on-chronic hepatitis B liver failure [J]. Journal of Shandong University (Health Sciences), 2024, 62(3): 61-69.
[13] DIAO Yujie, LIN Lin, LI Wenxuan, WANG Zhouyang, JIANG Bei, HU Yingying, LIU Guangyi. Neutrophil-to-platelet ratio predicts adverse renal outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis and its synergistic multifactor optimization model [J]. Journal of Shandong University (Health Sciences), 2024, 62(2): 60-68.
[14] LIU Yan, LENG Shanshan, XIA Xiaona, DONG Hao, HUANG Chencui, MENG Xiangshui. Functional outcomes of 376 patients with supratentorial spontaneous intracerebral hemorrhage based on radiomic parameters [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 59-67.
[15] CHEN Rong, YANG Yue, YANG Zhixiang, SU Yaying, PANG Zhiying, WANG Dawei, CUI Shujun, YANG Fei. Texture analysis based on CT to predict the short-term outcomes of acute pulmonary embolism [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 78-85.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd